Indiana Code
Chapter 35. Drug Utilization Review
12-15-35-28.5. Therapeutics Committee Duties

Sec. 28.5. The therapeutics committee established under section 20.5 of this chapter shall do the following:
(1) Advise and make recommendations to the board in the board's development and maintenance of a preferred drug list under section 28 of this chapter.
(2) Submit to the board a proposed preferred drug list that has been approved by a majority of a quorum of the therapeutics committee.
(3) Advise and make recommendations to the board in the board's review and maintenance of a preferred drug list.
As added by P.L.107-2002, SEC.18.

Structure Indiana Code

Indiana Code

Title 12. Human Services

Article 15. Medicaid

Chapter 35. Drug Utilization Review

12-15-35-1. "Appropriate and Medically Necessary" Defined

12-15-35-2. "Board" Defined

12-15-35-3. "Compendia" Defined

12-15-35-4. "Counseling" Defined

12-15-35-4.5. "Covered Outpatient Drug" Defined

12-15-35-5. "Criteria" Defined

12-15-35-6. "Drug-Disease Contraindication" Defined

12-15-35-7. "Drug-Drug Interaction" Defined

12-15-35-8. "Drug Utilization Review" or "Dur" Defined

12-15-35-9. "Intervention" Defined

12-15-35-10. "Overutilization or Underutilization" Defined

12-15-35-11. "Pharmacist" Defined

12-15-35-12. "Physician" Defined

12-15-35-13. "Prospective Dur" Defined

12-15-35-14. "Retrospective Dur" Defined

12-15-35-15. "Standards" Defined

12-15-35-16. "Surs" Defined

12-15-35-17. "Therapeutic Appropriateness" Defined

12-15-35-17.5. "Therapeutic Classification" or "Therapeutic Category" Defined

12-15-35-18. "Therapeutic Duplication" Defined

12-15-35-18.5. Application of Chapter

12-15-35-18.7. Formulary Requirements

12-15-35-19. Drug Utilization Review Board; Establishment

12-15-35-20. Membership of Board

12-15-35-20.1. Conflicts of Interest

12-15-35-20.5. Therapeutics Committee Established; Members; Limitations; Terms; Votes; Meetings

12-15-35-21. Board; Appointment; Term

12-15-35-22. Qualifications of Board Members

12-15-35-23. Physician Appointments; Geographic Balance

12-15-35-24. Reappointment of Members

12-15-35-25. Chairman; Compensation; Expenses

12-15-35-26. Additional Staff

12-15-35-27. Retrospective and Prospective Dur Program Responsibility

12-15-35-28. Duties of the Board; Preferred Drug List; Report

12-15-35-28.5. Therapeutics Committee Duties

12-15-35-28.7. Submitting Initial Preferred Drug List; Limitations on Restrictions; Advance Notice to Providers; Implementation; Prior Authorization Limitation; Rules

12-15-35-29. Quorum; Majority Vote on Dur Criteria and Standards for Prescribing

12-15-35-30. Local Practices; Monitoring

12-15-35-31. Intervention; Approval; Requisites

12-15-35-32. Repealed

12-15-35-32.1. Annual Report Contents

12-15-35-33. Repealed

12-15-35-34. Confidential Identifying Information; Release of Cumulative Nonidentifying Information

12-15-35-35. Prior Approval Program for Outpatient Drugs; Standards

12-15-35-36. Advisory Committees

12-15-35-37. Medicaid State Plan; Inclusion of Retrospective and Prospective Dur Program

12-15-35-38. Dur Program Guidelines and Procedures

12-15-35-39. Retrospective Dur Requisites

12-15-35-40. Prospective Dur Requisites

12-15-35-41. Board Activities Under Ic 34-30-15

12-15-35-42. Meetings

12-15-35-43. Confidentiality; Pharmacist Data and Information

12-15-35-43.5. Prohibiting the Release of Proprietary or Confidential Information Obtained Under Certain Circumstances

12-15-35-44. Confidentiality; Violations; Penalty

12-15-35-45. Outpatient Drug Formulary; Requirements

12-15-35-46. Review of Proposed Formulary

12-15-35-47. Review of Changes to Formulary

12-15-35-48. Board Review of Managed Care Organization Prescription Drug Program

12-15-35-49. Information Provided by Office

12-15-35-50. Maximum Allowable Cost Schedule for Drugs; Pharmacy Participation in Medicaid Program

12-15-35-51. Advisory Committee; Duties; Report